BACKGROUND: No meta-analysis is yet available for the risk of metabolic syndrome (MetS) following androgen deprivation therapy (ADT) for men with prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
To summarize the evidence for the link between ADT and MetS or its components quantitatively with a meta-analysis including all studies published to date.
METHODS: PubMed and Embase were searched using predefined inclusion criteria to perform meta-analyses on the association between metabolic syndrome, hyperglycemia, diabetes, hypertension, dyslipidemia or obesity and androgen deprivation therapy in patients with prostate cancer. Random effects methods were used to estimate pooled relative risks (RRs) and 95% confidence intervals (CI).
RESULTS: A total of nine studies was included. There was a positive association between ADT and risk of MetS (RR: 1.75 (95% CI: 1.27-2.41)). Diabetes was the only MetS component present in more than 3 studies, and also showed an increased risk following ADT (RR: 1.36 (95% CI: 1.17-1.58)).
CONCLUSION: This is the first quantitative summary addressing the potential risk of MetS following ADT in men with PCa. The positive RRs indicate that there is a need to further elucidate how type and duration of ADT affect these increased risks of MetS and diabetes as the number of men with PCa treated with ADT is increasing.
Bosco C, Crawley D, Adolfsson J, Rudman S, Van Hemelrijck M. Are you the author?
King's College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Group, London, United Kingdom; Department of Oncology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom; Karolinska Institute, CLINTEC Department, Stockholm, Sweden.
Reference: PLoS One. 2015 Mar 20;10(3):e0117344.